{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "VSTM",
  "name": "Verastem, Inc.",
  "url": "https://frontierpicks.com/dossiers/VSTM/",
  "json_url": "https://frontierpicks.com/dossiers/VSTM.json",
  "status": "DORMANT",
  "current_conviction": "MEDIUM",
  "graded_conviction": null,
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "Post-Q2 the narrative is confirmed and the tape has flattened: $6.74 on 2026-08-07 to $6.89 on 2026-08-21 while three banks cut targets with ratings held. The 2026-08-28 Oberland closing funds $50M inside 30 days; the October VS-7375 response-rate update is the binary and still sits outside the window.",
  "invalidation_trigger": "A weekly close below $5.50 unwinds the entire post-Q2 advance and returns price to the 2026-07-12 shelf, where the close was $5.53; the 2026-08-28 Oberland closing failing to fund $50M, or October passing with no VS-7375 response-rate disclosure, would compound the break.",
  "catalyst_date": "2026-08-28",
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "oncology-immunology",
    "precision-biotech-therapeutics"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "AVMAPKI FAKZYNJA CO-PACK holds accelerated approval (FDA, 2025-05-08); the RAMP 301 confirmatory topline is guided to mid-2027.",
    "The Oberland facility is a royalty financing secured against AVMAPKI FAKZYNJA revenue — non-dilutive to shareholders but an encumbrance on the only revenue-generating asset.",
    "Runway is guided into H2 2027 on a pro forma $201.4M cash position, while Phase 3 enrollment is targeted to begin H1 2027.",
    "October 2026 VS-7375 data is preliminary Phase 2 at roughly 20 patients per tumor type — cohort sizes that do not support cross-trial superiority claims.",
    "2026 reporting cadence has been 2026-05-07 (Q1) and 2026-08-06 (Q2); the Q3 date is not yet confirmed by the company.",
    "Single commercial product in a rare indication: quarterly revenue is sensitive to a small number of prescribing centers and to gross-to-net adjustments."
  ],
  "body_markdown": "## Current Thesis\nThe July gap between an accelerating KRAS science story and a tape that would not confirm it closed on 2026-08-06, and the two weeks since have been quiet. Q2 put AVMAPKI FAKZYNJA CO-PACK net product revenue at $25.1M against $23.093M consensus, total revenue at $40.1M versus $2.1M in Q2 2025, and a GAAP loss of $0.35 per share against a consensus $(0.43). The undated VS-7375 readout became \"October 2026,\" and a royalty facility with Oberland Capital replaced the equity-raise question with a funding date. Price went $5.53 (2026-07-12 close) to $6.74 (2026-08-07) to $6.89 (2026-08-21) — the second leg is roughly +2% over two weeks, with RSI(14) at 67.9 and price still 36.0% below the 52-week high of $10.77. What an investor is buying is a commercial low-grade serous ovarian cancer franchise that management expects to be self-sustaining by end-2026, funding a land-grab in oral KRAS G12D — with the repricing event, preliminary Phase 2 response rates across pancreatic, lung and colorectal cancer at roughly 20 patients per tumor type, still roughly two months out. Inside 30 days the only dated item is a financing close.\n\n## Bull Case\n- Q2 2026 (2026-08-06): total revenue $40.1M versus $2.1M in Q2 2025; co-pack net product revenue $25.1M against $23.093M consensus; GAAP net loss $34.7M, $0.35 per share, versus a $(0.43) consensus loss estimate.\n- Financing is non-dilutive and dated. Cash, equivalents and investments were $136.4M at 2026-06-30; pro forma $201.4M including the Oberland facility and a $15M COPIKTRA milestone from Secura Bio. $50M funds at closing on 2026-08-28; up to $25M more is available at the company's option if calendar-quarterly worldwide co-pack net sales reach $40M before 2027-05-15. Runway is guided into H2 2027.\n- The June dataset gave the October update a starting point: at a 2026-06-12 cutoff, VS-7375 was dosed at 600 mg once daily in 57 patients and 900 mg once daily in 25 patients with mostly low-grade GI toxicity, and 93% of 14 metastatic pancreatic patients at 900 mg showed a greater-than-50% CA19-9 reduction (2026-06-23 release). RAMP 205 showed 86% six-month survival in first-line metastatic pancreatic cancer (2026-06-17).\n- Three registration-directed Phase 2 trials dosed inside six weeks: TARGET-D 201 (2L metastatic PDAC) 2026-06-16, TARGET-D 202 (2L/3L NSCLC) 2026-07-22, TARGET-D 203 (metastatic CRC) 2026-07-28. FDA granted Fast Track to VS-7375 in KRAS G12D-mutated advanced NSCLC on 2026-06-03. Phase 2 enrollment completion is targeted by end-2026, an FDA meeting on Phase 3 design before year-end, Phase 3 enrollment initiation in H1 2027.\n- Every covering bank named in the last two months holds a Buy or Outperform: HC Wainwright $18 and BTIG $18 (both 2026-06-24), RBC $14 (2026-07-07), Mizuho $13 (2026-08-11), Guggenheim $12 (2026-08-07) — a $12–$18 band against the 2026-08-21 close of $6.89.\n\n## Bear Case\n- The direction of sell-side revisions is down while the tape is up. RBC cut to $14 on 2026-07-07, Guggenheim to $12 on 2026-08-07, Mizuho to $13 on 2026-08-11. That is three cuts in six weeks with no rating changes — the prior note flagged \"a third target cut\" as the observable that would confirm this risk, and it has now printed.\n- October is preliminary Phase 2 data at roughly 20 patients per tumor type. Cohorts that size support a directional read on activity, and cannot settle superiority against Revolution Medicines' RMC-9805 or the Astellas and BMS programs aimed at the same mutation.\n- The contingent $25M Oberland tranche requires quarterly co-pack net sales of $40M before 2027-05-15, against $25.1M booked in Q2 2026. That is a large step-up on a rare-indication launch and it carries a hard expiry.\n- The royalty facility is non-dilutive to shareholders but encumbers the one revenue-generating asset. Runway guided into H2 2027 runs against Phase 3 enrollment starting H1 2027, so the spend commitment ramps before the funded window ends.\n- AVMAPKI FAKZYNJA holds accelerated approval (FDA, 2025-05-08); the RAMP 301 confirmatory topline is not guided until mid-2027, so conditional-approval risk stays live for roughly a year.\n- Price is 36.0% below the $10.77 52-week high despite gaining 62.5% over three months. The Q2 beat did not carry price back toward the June levels.\n\n## Setup & Price Structure\n- Reference close 2026-08-21: $6.89. Three-month price change +62.5%. RSI(14) 67.9. Distance from the 52-week high of $10.77: -36.0%.\n- The post-print leg has flattened: $6.74 on 2026-08-07 to $6.89 on 2026-08-21, with RSI essentially unchanged (68.1 to 67.9). Momentum has been held, not extended.\n- The structure being defended is the post-Q2 shelf built off the 2026-07-12 close of $5.53. A weekly close below $5.50 would hand back the entire earnings-and-financing advance.\n- **The narrative is maturing.** The repricing headlines are dated 2026-06-17 (RAMP 205), 2026-06-23 (TARGET-D 101), 2026-08-06 (Q2 plus Oberland). Since then the only new item is 2026-08-11, a price-target cut. Attention exists and the name is known; the incremental bid has thinned while the next catalyst sits outside the window.\n- Crowding and positioning observables, stated as observables: RSI(14) at 67.9 with price still a third below the 52-week high; five price targets clustered $12–$18 while three of them were reduced inside six weeks; the capital raise took a royalty form rather than equity, and no offering has been announced since the Q2 print as of 2026-08-21; the nearest dated event is a financing close rather than a data release.\n\n## Catalyst Calendar (next 30 days)\n- **2026-08-28** — Closing of the Oberland Capital royalty financing, $50M funded. The one dated item inside the window.\n- **~2026-09-30 (est.)** — No company-confirmed event between the Oberland close and the October data update; the company has not guided a September disclosure.\n- **~2026-10-31 (est.)** — VS-7375 TARGET-D update: response rates across PDAC, NSCLC and CRC, roughly 20 patients per tumor type. Outside 30 days.\n- **~2026-11-05 (est.)** — Q3 2026 results, on the 2026-05-07 / 2026-08-06 cadence; date not confirmed by the company.\n\n## What Would Change Our Mind\nThe structure at risk is the shelf laid down between the 2026-07-12 close of $5.53 and the 2026-08-07 close of $6.74 — the whole advance is the market paying for a revenue beat plus a non-dilutive financing plus a dated readout. A weekly close below $5.50 removes all three from the price and puts the name back where it sat when the catalyst had no date. Three other things would flip the read independent of price: the 2026-08-28 Oberland closing failing to fund $50M, which reopens the equity-issuance question the Q2 print was supposed to have closed; October ending with no VS-7375 response-rate disclosure, which returns the binary to the undated state that made this untradeable in July; and a Q3 print (~2026-11-05 est.) with co-pack net product revenue at or below the $25.1M booked in Q2, which would put the $40M quarterly bar for the contingent tranche out of reach and undercut the self-sustaining-by-end-2026 claim. A fourth rating action taking a target below $10 would mark the sell-side band converging toward the tape rather than the reverse.\n\n## Correlation Notes\n- Direct read-across to the oral KRAS G12D complex: Revolution Medicines (RMC-9805), Astellas and BMS. A competitor PDAC or NSCLC dataset landing in the same October window is the single most likely source of an exogenous move.\n- Partner GenFleet Therapeutics runs a Phase 1/2 monotherapy study of the same molecule (GFH375) in China; its data releases move VSTM off the US trial cadence.\n- Unprofitable, single-product commercial-stage biotech trades with small-cap biotech beta (XBI) and with rate expectations; the 62.5% three-month advance was earned on company events, but the drawdown correlation to the sector is not company-specific.\n- The revenue line is a single-indication launch (LGSOC). Payer, prescriber-uptake and gross-to-net commentary at the Q3 print drives the co-pack number more than anything in the KRAS pipeline does.",
  "first_seen": "2026-07-12",
  "last_analyzed": "2026-08-22T11:23:38+00:00",
  "last_synthesized": "2026-08-22",
  "last_update_source": "watchlist_research",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}